In order to investigate the influence of IL-1β levels on the granulomatous response, IL-1β was blocked throughout the infection using gevokizumab (Issafras et al., 2014) and granuloma formation was monitored on day 7 post-infection . The gene discussed is IL1B; the disease is infection.